The goal of the current studies was to create a topical gel that contained griseofulvin's nanostructured lipid carriers (NLCs) and evaluate how well it worked for superficial infections. Using a variety of lipids and surfactants, including oleic acid, glyceryl monostearate, pluronic F 68, and tween 80, the drug solubility tests were carried out. Box-Behnken design (BBD) was used to optimize the lipid, surfactant, and emulsifier concentrations. Superosonication was used to create microemulsions. The optimized batch (F12), which contained 0.2% w/w drug, 2% GMS, 2% Pluronic F68, and Tween 80 (in a 1:1 ratio) showed a particle size of 209 nm, a zeta potential of -44.12 mV, an entrapment level of 85.24%, and a drug release of 92.12% after the prepared batches (F1 to F15) were analyzed. The topical gel was made with 1.5% carbopol 940. Biochemical investigations showed that, in comparison to the typical medication, griseofulvin-loaded nanogel significantly reduced lipid peroxidation. Studies on the cytotoxicity of nanogel in vitro revealed increased safety for human keratinocyte cells (HaCaT). Using T.rubrum and M.canis fungal strains, the findings of antifungal activity demonstrated complete clinical and mycological cure against superficial infections including Tenia pedis as well as ringworm in Wistar rats in a period of 21 days. These preclinical studies have demonstrated that nanogels are a more promising treatment option than currently available medications for the aforementioned superficial infection